Introduction:
Welcome to StartupBubble.news, where we bring you the latest innovations and groundbreaking startups from around the world. In this edition of Startup Showcase, we delve into the world of FathomX, a Digital Health AI spin-off company from the National University of Singapore. FathomX is on a mission to enhance breast cancer analysis and revolutionize mammogram screenings with their cutting-edge AI technology.
A Game-Changing Solution for Breast Cancer Analysis:
At the core of FathomX’s offerings lies their flagship product, FxMammo. FxMammo is an AI Assistant designed to significantly improve the screening procedure for mammograms. By reducing false positive rates by up to 67% and enhancing the clinical workflow, FxMammo streamlines the breast cancer screening process. This breakthrough solution saves valuable time for both patients and medical professionals while improving the accuracy of diagnoses.
The Evolution of FathomX’s AI Model
FathomX’s unique AI model for mammograms originated from the global competition known as The Dream Challenge, organized by the United States’ White House. As the top Asian team among more than 100 participants worldwide, FathomX’s founders saw the immense potential of their AI model and decided to spin-off the company with the support of NUS Enterprise. Since then, the AI model has undergone significant advancements in predictive accuracy, refinement, and user preferences to cater to evolving needs.
Collaborations and Recognition
Within a year of its inception, FathomX has formed key research collaborations with major hospitals such as the National University Hospital and Kandang Kerbau Women and Children’s Hospital in Singapore, Tokyo Medical and Dental University in Japan, and Taipei Medical University in Taiwan. These partnerships allow FathomX to leverage real-world data and further refine their AI algorithms to improve breast cancer detection rates.
On the commercialization front, FathomX has signed a co-investment and co-development deal with Hewlett Packard Enterprise (HPE). This strategic partnership grants FathomX access to HPE’s engineering team and potential exposure to over 130 hospital clients in the APAC region. Additionally, FathomX has executed a data transfer agreement with multiple research agencies, including Lifepool at the Peter MacCallum Cancer Centre in Australia. Furthermore, FathomX’s accomplishments have not gone unnoticed. The company recently secured SGD 1.25 million in I2Start funding Pathway and is a finalist in the prestigious MedTech Innovator competition in Singapore. Their success has been featured in various media outlets, including Channel News Asia, Tamil Seithi, Channel 8 News, Enterprise SPARKS, and even TEDx. FathomX has also emerged as a champion or finalist in several notable competitions, such as the Hubei Innovate Challenge, Qingdao Innovation Challenge, IET Innovation Award Shortlist, and the SHE1K C-Shark Tank Competition.
Conclusion:
FathomX’s innovative approach to breast cancer analysis through AI technology has the potential to revolutionize mammogram screenings worldwide. With their flagship product, FxMammo, FathomX aims to significantly improve the efficiency and accuracy of breast cancer diagnoses, ultimately saving lives.
Website: https://www.fathomx.co/
Looking to promote your brand to a targeted audience of startup founders, investors, and C-level executives? Check out our advertising opportunities and sponsored articles at StartupBubble.news! Reach out to us at [email protected] to discuss how we can help amplify your brand’s visibility and drive results. Don’t miss out on this opportunity to connect with our engaged readership. Contact us today!
